Sen Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sen Yan has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Changtao Jiang
Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China
2 shared publications - Chuan Ye
Department of Biomedical Informatics, School of Basic Medical Sciences, Peking University, Beijing 100191, China
2 shared publications - Min Zhao
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
2 shared publications - Pengyan Xia
Peking University
2 shared publications Qixing Nie
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Center for Reproductive Medicine, Third Hospital, Peking University, Beijing, China
2 shared publications- Yanli Pang
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital Key Laboratory of Assisted Reproduction, Peking University, Ministry of Education Beijing Key Laboratory of Collaborative Innovation in Frontier Technologies for Population Quality Beijing China
2 shared publications
Latest Publications
- 22 August 2026
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 60 (39) , 27595-27606
Restoration of Gut Microbiota Vertical Transmission by Bifidobacterium Mitigates Pollutant-Induced Intergenerational Obesity
Mass production and widespread distribution of environmental pollutants enhance human susceptibility to disease, which may be related to gut microbial communities. However, the link between the transgenerational toxic effects of environmental pollutants and animal gut microbial communities remains obscure. Here, we show that environmental dose p,p’-DDE (a typical environmental pollutant) exposure prepregnancy reshapes offspring metabolic homeostasis through vertical transmission of the maternal gut microbiota, inducing the development of obesity. In addition, by taking cross-sectional temporal sampling strategy, we show that Bifidobacterium, whose metabolic production of acetate can interfere with obesity by activating Gpr41 and Gpr43, is the key species responsible for this outcome. Supplementation of Bifidobacterium or acetate in dams or offspring reversed the obesity phenotype in offspring mice. Finally, we confirmed the mechanism by which p,p’-DDE induces oxidative stress to inhibit the growth of Bifidobacteriumin vitro, and this phenomenon was found to be mechanically applicable to a wider range of organochlorine pesticides. In conclusion, our study shows that p,p’-DDE can reshape offspring metabolic phenotype through selective vertical transmission of maternal gut microbiota, and maternal or offspring supplementation with Bifidobacterium may be a promising intervention.
- 22 August 2026
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 60 (39) , 27595-27606
Restoration of Gut Microbiota Vertical Transmission by Bifidobacterium Mitigates Pollutant-Induced Intergenerational Obesity
Mass production and widespread distribution of environmental pollutants enhance human susceptibility to disease, which may be related to gut microbial communities. However, the link between the transgenerational toxic effects of environmental pollutants and animal gut microbial communities remains obscure. Here, we show that environmental dose p,p’-DDE (a typical environmental pollutant) exposure prepregnancy reshapes offspring metabolic homeostasis through vertical transmission of the maternal gut microbiota, inducing the development of obesity. In addition, by taking cross-sectional temporal sampling strategy, we show that Bifidobacterium, whose metabolic production of acetate can interfere with obesity by activating Gpr41 and Gpr43, is the key species responsible for this outcome. Supplementation of Bifidobacterium or acetate in dams or offspring reversed the obesity phenotype in offspring mice. Finally, we confirmed the mechanism by which p,p’-DDE induces oxidative stress to inhibit the growth of Bifidobacteriumin vitro, and this phenomenon was found to be mechanically applicable to a wider range of organochlorine pesticides. In conclusion, our study shows that p,p’-DDE can reshape offspring metabolic phenotype through selective vertical transmission of maternal gut microbiota, and maternal or offspring supplementation with Bifidobacterium may be a promising intervention.
- Open Access
- 4 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α
Non-alcoholic steatohepatitis (NASH) is a severe type of the non-alcoholic fatty liver disease (NAFLD). NASH is a growing global health concern due to its increasing morbidity, lack of well-defined biomarkers and lack of clinically effective treatments. Using metabolomic analysis, the most significantly changed active lipid sphingosine d18:1 [So(d18:1)] is selected from NASH patients. So(d18:1) inhibits macrophage HIF-2α as a direct inhibitor and promotes the inflammatory factors secretion. Male macrophage-specific HIF-2α knockout and overexpression mice verified the protective effect of HIF-2α on NASH progression. Importantly, the HIF-2α stabilizer FG-4592 alleviates liver inflammation and fibrosis in NASH, which indicated that macrophage HIF-2α is a potential drug target for NASH treatment. Overall, this study confirms that So(d18:1) promotes NASH and clarifies that So(d18:1) inhibits the transcriptional activity of HIF-2α in liver macrophages by suppressing the interaction of HIF-2α with ARNT, suggesting that macrophage HIF-2α may be a potential target for the treatment of NASH.
- 4 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessSphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α
Non-alcoholic steatohepatitis (NASH) is a severe type of the non-alcoholic fatty liver disease (NAFLD). NASH is a growing global health concern due to its increasing morbidity, lack of well-defined biomarkers and lack of clinically effective treatments. Using metabolomic analysis, the most significantly changed active lipid sphingosine d18:1 [So(d18:1)] is selected from NASH patients. So(d18:1) inhibits macrophage HIF-2α as a direct inhibitor and promotes the inflammatory factors secretion. Male macrophage-specific HIF-2α knockout and overexpression mice verified the protective effect of HIF-2α on NASH progression. Importantly, the HIF-2α stabilizer FG-4592 alleviates liver inflammation and fibrosis in NASH, which indicated that macrophage HIF-2α is a potential drug target for NASH treatment. Overall, this study confirms that So(d18:1) promotes NASH and clarifies that So(d18:1) inhibits the transcriptional activity of HIF-2α in liver macrophages by suppressing the interaction of HIF-2α with ARNT, suggesting that macrophage HIF-2α may be a potential target for the treatment of NASH.
- Top Cited Papers
- 20 May 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (5) , 947-962
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
Polycystic ovary syndrome (PCOS), an endocrine disorder afflicting 6–20% of women of reproductive age globally, has been linked to alterations in the gut microbiome. We previously showed that in PCOS, elevation of Bacteroides vulgatus in the gut microbiome was associated with altered bile acid metabolism. Here we show that B. vulgatus also induces a PCOS-like phenotype in female mice via an alternate mechanism independent of bile acids. We find that B. vulgatus contributes to PCOS-like symptoms through its metabolite agmatine, which is derived from arginine by arginine decarboxylase. Mechanistically, agmatine activates the farnesoid X receptor (FXR) pathway to subsequently inhibit glucagon-like peptide-1 (GLP-1) secretion by L cells, which leads to insulin resistance and ovarian dysfunction. Critically, the GLP-1 receptor agonist liraglutide and the arginine decarboxylase inhibitor difluoromethylarginine ameliorate ovarian dysfunction in a PCOS-like mouse model. These findings reveal that agmatine–FXR–GLP-1 signalling contributes to ovarian dysfunction, presenting a potential therapeutic target for PCOS management.
- 20 May 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (5) , 947-962
Top Cited PapersThe microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
Polycystic ovary syndrome (PCOS), an endocrine disorder afflicting 6–20% of women of reproductive age globally, has been linked to alterations in the gut microbiome. We previously showed that in PCOS, elevation of Bacteroides vulgatus in the gut microbiome was associated with altered bile acid metabolism. Here we show that B. vulgatus also induces a PCOS-like phenotype in female mice via an alternate mechanism independent of bile acids. We find that B. vulgatus contributes to PCOS-like symptoms through its metabolite agmatine, which is derived from arginine by arginine decarboxylase. Mechanistically, agmatine activates the farnesoid X receptor (FXR) pathway to subsequently inhibit glucagon-like peptide-1 (GLP-1) secretion by L cells, which leads to insulin resistance and ovarian dysfunction. Critically, the GLP-1 receptor agonist liraglutide and the arginine decarboxylase inhibitor difluoromethylarginine ameliorate ovarian dysfunction in a PCOS-like mouse model. These findings reveal that agmatine–FXR–GLP-1 signalling contributes to ovarian dysfunction, presenting a potential therapeutic target for PCOS management.